BR112020005455A2 - derivados de iminopirimidina cíclica como inibidores de cinase - Google Patents
derivados de iminopirimidina cíclica como inibidores de cinase Download PDFInfo
- Publication number
- BR112020005455A2 BR112020005455A2 BR112020005455-0A BR112020005455A BR112020005455A2 BR 112020005455 A2 BR112020005455 A2 BR 112020005455A2 BR 112020005455 A BR112020005455 A BR 112020005455A BR 112020005455 A2 BR112020005455 A2 BR 112020005455A2
- Authority
- BR
- Brazil
- Prior art keywords
- quinazolin
- oxy
- sulfonamide
- propane
- dihydroimidazo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762561142P | 2017-09-20 | 2017-09-20 | |
| US62/561,142 | 2017-09-20 | ||
| PCT/US2018/052047 WO2019060611A1 (en) | 2017-09-20 | 2018-09-20 | CYCLIC IMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF KINASES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020005455A2 true BR112020005455A2 (pt) | 2020-09-24 |
Family
ID=64457074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020005455-0A BR112020005455A2 (pt) | 2017-09-20 | 2018-09-20 | derivados de iminopirimidina cíclica como inibidores de cinase |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11254680B2 (enExample) |
| EP (1) | EP3684772B1 (enExample) |
| JP (1) | JP7394768B2 (enExample) |
| KR (1) | KR102796209B1 (enExample) |
| CN (1) | CN111247152B (enExample) |
| AU (1) | AU2018338098B2 (enExample) |
| BR (1) | BR112020005455A2 (enExample) |
| CA (1) | CA3076202A1 (enExample) |
| MX (1) | MX2020003126A (enExample) |
| WO (1) | WO2019060611A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3684772B1 (en) * | 2017-09-20 | 2023-12-06 | ABM Therapeutics Corporation | Cyclic iminopyrimidine derivatives as kinase inhibitors |
| TWI817018B (zh) * | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
| MX2022006711A (es) * | 2019-12-10 | 2022-07-12 | Hoffmann La Roche | Nuevos inhibidores de braf como rompedores de la paradoja. |
| US12303509B2 (en) | 2020-06-09 | 2025-05-20 | Pfizer Inc. | Compounds for the treatment of BRAF-associated diseases and disorders |
| CA3179671A1 (en) * | 2020-08-07 | 2022-02-10 | Abm Therapeutics Corporation | Kinase inhibitors and uses thereof |
| CN114380697A (zh) * | 2021-11-30 | 2022-04-22 | 上海毕得医药科技股份有限公司 | 一种n-甲基乙基胺盐酸盐的制备工艺 |
| TW202409040A (zh) * | 2022-07-19 | 2024-03-01 | 大陸商西藏海思科製藥有限公司 | 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途 |
| CN117209503B (zh) * | 2023-09-13 | 2025-10-17 | 苏州翔实医药发展有限公司 | 一种5,6-二氢咪唑并[1，2-c]喹唑啉及其衍生物合成的方法 |
| WO2025108405A1 (zh) * | 2023-11-22 | 2025-05-30 | 西藏海思科制药有限公司 | 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途 |
| WO2025153057A1 (zh) * | 2024-01-17 | 2025-07-24 | 海思科医药集团股份有限公司 | 一种含braf抑制剂的药物组合物及其在医药上的应用 |
| WO2025176185A1 (zh) * | 2024-02-23 | 2025-08-28 | 海思科医药集团股份有限公司 | 一种braf抑制剂的制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20131159B1 (hr) * | 2002-09-30 | 2019-11-01 | Bayer Ip Gmbh | Taljeni azol-pirimidin derivati |
| PE20081581A1 (es) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
| JP5291095B2 (ja) | 2007-06-01 | 2013-09-18 | グラクソスミスクライン エルエルシー | イミダゾピリジンキナーゼ阻害剤 |
| SG183036A1 (en) | 2007-07-17 | 2012-08-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| EP2348020A1 (en) | 2009-12-23 | 2011-07-27 | Esteve Química, S.A. | Preparation process of erlotinib |
| AU2011337461B2 (en) | 2010-12-02 | 2015-04-02 | Bisichem Co., Ltd. | Novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against Raf kinase, containing same as active ingredient |
| US20130023531A1 (en) | 2011-01-27 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors |
| WO2012118492A1 (en) | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
| US8889741B2 (en) | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
| MX2015003196A (es) * | 2012-09-14 | 2015-07-06 | Eternity Bioscience Inc | Derivados de aminoisoquinolina como inhibidores de la proteina quinasa. |
| CN104812389B (zh) | 2012-09-24 | 2020-07-17 | 润新生物公司 | 某些化学实体、组合物及方法 |
| US9321762B2 (en) | 2013-12-11 | 2016-04-26 | Development Center For Biotechnology | Quinazoline compounds, method for preparing the same and use thereof |
| CN105272970A (zh) | 2014-07-03 | 2016-01-27 | 中国药科大学 | 基于色原酮结构的Raf激酶抑制剂及其制备方法和用途 |
| JP6826526B6 (ja) | 2014-07-16 | 2021-03-31 | ディベロップメント センター フォー バイオテクノロジーＤｅｖｅｌｏｐｍｅｎｔ Ｃｅｎｔｅｒ Ｆｏｒ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ | キノキサリン化合物、それを調製する方法およびその使用 |
| EP3684772B1 (en) * | 2017-09-20 | 2023-12-06 | ABM Therapeutics Corporation | Cyclic iminopyrimidine derivatives as kinase inhibitors |
-
2018
- 2018-09-20 EP EP18808139.2A patent/EP3684772B1/en active Active
- 2018-09-20 CN CN201880067947.0A patent/CN111247152B/zh active Active
- 2018-09-20 BR BR112020005455-0A patent/BR112020005455A2/pt active IP Right Grant
- 2018-09-20 US US16/648,908 patent/US11254680B2/en active Active
- 2018-09-20 WO PCT/US2018/052047 patent/WO2019060611A1/en not_active Ceased
- 2018-09-20 KR KR1020207010704A patent/KR102796209B1/ko active Active
- 2018-09-20 MX MX2020003126A patent/MX2020003126A/es unknown
- 2018-09-20 JP JP2020538750A patent/JP7394768B2/ja active Active
- 2018-09-20 AU AU2018338098A patent/AU2018338098B2/en active Active
- 2018-09-20 CA CA3076202A patent/CA3076202A1/en active Pending
-
2022
- 2022-01-13 US US17/575,292 patent/US11932647B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018338098B2 (en) | 2024-02-22 |
| JP2020534373A (ja) | 2020-11-26 |
| KR20200055034A (ko) | 2020-05-20 |
| WO2019060611A1 (en) | 2019-03-28 |
| EP3684772A1 (en) | 2020-07-29 |
| CA3076202A1 (en) | 2019-03-28 |
| JP7394768B2 (ja) | 2023-12-08 |
| RU2020113707A3 (enExample) | 2021-12-23 |
| US20200247813A1 (en) | 2020-08-06 |
| CN111247152A (zh) | 2020-06-05 |
| EP3684772C0 (en) | 2023-12-06 |
| US11254680B2 (en) | 2022-02-22 |
| MX2020003126A (es) | 2020-10-01 |
| EP3684772B1 (en) | 2023-12-06 |
| US11932647B2 (en) | 2024-03-19 |
| RU2020113707A (ru) | 2021-10-20 |
| KR102796209B1 (ko) | 2025-04-16 |
| US20220251089A1 (en) | 2022-08-11 |
| CN111247152B (zh) | 2024-07-16 |
| AU2018338098A1 (en) | 2020-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112020005455A2 (pt) | derivados de iminopirimidina cíclica como inibidores de cinase | |
| US10947246B2 (en) | Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof | |
| CN106687450B (zh) | 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法 | |
| CN107108671B (zh) | 作为raf激酶抑制剂的化合物和组合物 | |
| BR112012018415A2 (pt) | composto, composição, métodos de preparar uma composição e de tratamento, e, uso de um composto. | |
| PT1339663E (pt) | Derivados de naftaleno | |
| CN105646389A (zh) | 一种作为吲哚胺-2,3-双加氧酶抑制剂的氨基磺酸脂及其制备方法和用途 | |
| JP2019507779A (ja) | 尿素系化合物、その製造方法及びその医薬用途 | |
| KR20180114057A (ko) | 피리미딘 7-원 고리 화합물, 이의 제조 방법, 이의 약제학적 조성물, 및 이의 용도 | |
| CA3135921C (en) | Quinolyl-containing compound and pharmaceutical composition, and use thereof | |
| CN106795152A (zh) | 蛋白激酶抑制剂 | |
| TWI828489B (zh) | 具有mat2a抑制活性的嘧啶-2(1h)-酮并二環類化合物及其用途 | |
| US12090150B2 (en) | Deuterated analogs of elacridar | |
| US11225474B2 (en) | Crystalline salt forms of 3-(1,2,4-triazolo[4,3-a]pyridine-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-trifluoromethylphenyl)benzamide for medical application | |
| EP3242881B1 (en) | Furoquinolinediones as inhibitors of tdp2 | |
| US20240083844A1 (en) | Kinase inhibitors and uses thereof | |
| RU2801302C2 (ru) | Производные циклического иминопиримидина в качестве ингибиторов киназ | |
| TW201922690A (zh) | 環－amp反應元素結合蛋白的抑制劑 | |
| ES2710199T3 (es) | Nuevos inhibidores de PI3K/AKT/mTOR y usos farmacéuticos de los mismos | |
| JP2021518855A (ja) | Ｗｎｔシグナル伝達経路阻害剤としてのピラゾール誘導体 | |
| BR112019025158A2 (pt) | Derivados de ácido carboxílico como inibidores das proteínas quinase | |
| HK40031627B (zh) | 作为激酶抑制剂的环状亚氨基嘧啶衍生物 | |
| WO2019015689A1 (zh) | 手性3-奎宁环酮类化合物、制备方法及用途 | |
| HK40031627A (en) | Cyclic iminopyrimidine derivatives as kinase inhibitors | |
| US9321766B1 (en) | Kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B09X | Republication of the decision to grant [chapter 9.1.3 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/09/2018, OBSERVADAS AS CONDICOES LEGAIS |